Abstract
The objective of this study was to evaluate the pharmacokinetics and abuse potential of different formulations of oxycodone. The participants completed an 8-day, placebo-controlled trial with four phases: naloxone challenge, double-blind drug discrimination, double-blind abuse liability, and discontinuation. Nineteen healthy, male, recreational drug abusers participated in this study. The participants were administered different doses and formulations of oxycodone (40 mg immediate release [IR], 40 mg controlled release [CR], crushed 40 mg CR, and 80 mg CR) to evaluate pharmacokinetic parameters and ratings of drug liking and high. Pharmacokinetic parameters were determined over a 12-hour dosing interval. The primary pharmacodynamic endpoints were two questions from the Drug Effects Questionnaire ("Do you like the drug?" and "How high are you now?"). Maximal plasma concentrations and area under the curve determinations were similar for 40 mg IR, crushed 40 mg CR, and 80 mg CR, which were all greater than 40 mg CR. For drug liking and high, the maximal effect and area under the effect curve were similar for the three formulations, which were all greater than 40 mg CR. The dose required to produce comparable reports of drug liking...Continue Reading
References
Jan 1, 1992·Psychopharmacology·H de WitJ Ambre
Dec 1, 1991·British Journal of Addiction·M Farré, J Camí
Mar 1, 1995·Clinical Pharmacology and Therapeutics·G K MumfordR R Griffiths
Dec 1, 1996·British Journal of Clinical Pharmacology·J W MandemaD R Stanski
Jan 3, 2001·Anesthesiology·M S AngstD R Stanski
Apr 9, 2001·Psychopharmacology·M E AbreuS L Walsh
Aug 20, 2003·Journal of Psychoactive Drugs·Donald R Wesson, Walter Ling
Sep 2, 2004·Journal of Addictive Diseases·Lon R Hays
Sep 16, 2004·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·UNKNOWN American Academy of Pain MedicineUNKNOWN American Society of Addiction Medicine
Jul 18, 2006·Addictive Behaviors·Sean Esteban McCabeChristian J Teter
Jul 25, 2006·Pharmacoepidemiology and Drug Safety·Leonard J PaulozziYongli Xi
Sep 22, 2007·The Clinical Journal of Pain·Nathaniel P KatzRoger Weiss
Mar 25, 2008·Therapeutics and Clinical Risk Management·Sujata S Jayawant, Rajesh Balkrishnan
Feb 4, 2009·The Journal of Pain : Official Journal of the American Pain Society·Roger ChouChristine Miaskowski
Apr 1, 2009·Postgraduate Medicine·Christopher T AquinaMark A Merlin
May 16, 2009·Drug and Alcohol Dependence·Lawrence P Carter, Roland R Griffiths
Sep 10, 2009·Journal of Opioid Management·Sandra D ComerRichard W Foltin
Sep 12, 2009·Drug and Alcohol Dependence·Robert L BalsterSharon L Walsh
Jan 16, 2010·Journal of Clinical Psychopharmacology·Megan J ShramEdward M Sellers
Feb 2, 2010·Journal of the National Cancer Institute·Rajeshwari SridharaRichard Pazdur
Sep 25, 2010·Journal of Opioid Management·Stephen F ButlerSimon H Budman
Apr 6, 2011·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Beatrice SetnikLynn Webster
Aug 10, 2011·Journal of Opioid Management·Lynn WebsterEric Voth
Citations
May 17, 2013·Clinical Drug Investigation·Peter J PerrinoStephen C Harris
Oct 16, 2013·Peptides·Richard J Bodnar
Dec 29, 2012·Psychopharmacology·Meghan E MoreanStephanie S O'Malley
Oct 26, 2012·Postgraduate Medicine·Marco Pappagallo, Marta Sokolowska
Aug 21, 2014·Postgraduate Medicine·Terri MortonLynn Webster
Jul 7, 2015·Drug Development and Industrial Pharmacy·Tiffani D EisenhauerThomas Barrett
Jul 25, 2015·Acta Anaesthesiologica Taiwanica : Official Journal of the Taiwan Society of Anesthesiologists·Joseph V PergolizziJack E Henningfield
Jun 12, 2013·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Beatrice SetnikLynn Webster
Jan 28, 2016·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Lynn R WebsterAlison B Fleming
Aug 26, 2015·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Terri L MortonLynn Webster
Dec 13, 2012·Addiction Biology·Camron D BryantRiyan Cheng
Mar 13, 2014·Acta Anaesthesiologica Scandinavica·L PedersenO M S Fredheim
Dec 3, 2013·Clinical Therapeutics·Thomas B Gregory
Jan 30, 2015·Frontiers in Behavioral Neuroscience·Stacey L Kirkpatrick, Camron D Bryant
Jun 23, 2016·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Mona DarwishLynn R Webster
Aug 24, 2016·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Beatrice SetnikGernot Wolfram
Jul 23, 2016·Journal of Clinical Pharmacology·Beatrice SetnikLynn Webster
Sep 7, 2016·Pharmacoepidemiology and Drug Safety·Theodore J CiceroZachary A Kasper
Sep 4, 2018·Expert Opinion on Drug Discovery·Joseph V PergolizziRobert B Raffa
Nov 8, 2018·Expert Review of Clinical Pharmacology·Andrea FanelliDaniela Ghisi
Dec 12, 2018·Journal of Clinical Psychopharmacology·Karin GöhlerMarie-Henriette Eerdekens
Aug 6, 2017·The Journal of Pharmacology and Experimental Therapeutics·Takahiro MiyazakiStephen K Doberstein
Jul 31, 2019·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Jeffrey GudinJohn Markman
Sep 26, 2019·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Xue GeMichael A Eldon
Mar 25, 2017·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Lynn WebsterMichael A Eldon
Feb 29, 2020·Cellular and Molecular Neurobiology·Caroline M KopruszinskiFrank Porreca
Nov 5, 2019·Clinical Drug Investigation·Zhu LuoYali Shen
Jun 1, 2018·Pain Research & Management : the Journal of the Canadian Pain Society = Journal De La Société Canadienne Pour Le Traitement De La Douleur·Lynn R WebsterStefan Aigner
Jan 18, 2019·Clinical Pharmacokinetics·Mari KinnunenMerja Kokki
Oct 28, 2019·Pharmaceutical Research·Liang ZhengLing Wang
Nov 2, 2016·Journal of Clinical Pharmacology·Ernest A KopeckyEdward M Sellers
Nov 28, 2020·Cellular and Molecular Neurobiology·Cherkaouia KibalyCatherine M Cahill
May 14, 2021·Clinical and Translational Science·Saeid RaofiMyong-Jin Kim